SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Intarcia Therapeutics, Inc. Presents Compelling 48-week Results for ITCA 650 - Data Underlines the Promise to Become the First Injection-free GLP-1 Therapy at the 47th Annual EASD Meeting in Lisbon